Merck & Co. (MRK, Pharmaceuticals) Stock Valuation & Fair Value Significantly overvalued
Merck & Co. (MRK, Pharmaceuticals) trades at a blended P/E of 33.7, about 140% above its historical normal valuation, with a forward growth estimate of 49.2% and a PEG of 0.68. Analysts' one-year estimates have been hit 82% of the time. Priced at its historical normal P/E of 14.0 on the same blended earnings, the 2026-10-02 close of $144.30 corresponds to about $60.10 a share. This is a valuation reference, not a price target.
- Price $142.38 at the 2026-10-08 close, 2.2% below the 20-day average ($145.65) and 0.2% below the 50-day ($142.61).
- RSI (14) at 45.0.
- 52-week range $80.14 to $155.53: the price is 8.5% below the high and 77.7% above the low.
- At its last earnings report the options market priced a 3.9% move.
The Street vs SeerForecast
Wall Street's mean price target for MRK is $155.76 across 25 analysts, 9.4% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.
Valuation flags
- Overvalued by 140%
Verdict history
tickerseer's rating moved from favorable on our tests (2026-06-03) to significantly overvalued (2026-10-05). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 37 weeks
Earnings moves: MRK moved more than the options market implied in 0 of 1 recent tracked reports.
Frequently asked questions
Is Merck & Co. stock overvalued?
At a blended P/E of 33.7 versus its historical normal P/E of 14.0, Merck & Co. trades about 140% above its typical valuation, with a PEG of 0.68 on 49.2% forward growth. tickerseer currently rates it significantly overvalued.
What is Merck & Co.'s fair value and PEG?
Merck & Co. trades at a blended P/E of 33.7 against a historical normal P/E of 14.0, a PEG of 0.68, and a forward growth estimate of 49.2%. Priced at its historical normal P/E of 14.0 on the same blended earnings, the 2026-10-02 close of $144.30 corresponds to about $60.10 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Merck & Co. changed?
tickerseer's rating moved from favorable on our tests (2026-06-03) to significantly overvalued (2026-10-05). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
What is the analyst price target for Merck & Co.?
The mean Wall Street price target for Merck & Co. is $155.76 across 25 analysts, 9.4% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.